A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.

Elena Maria ToscaN TerranovaK StuyckensA G DosneT PereraJ VialardP KingT VerhulstJ J Perez-RuixoP MagniI Poggesi

Published in: Cancer chemotherapy and pharmacology (2021)

The successful modeling exercise of erdafitinib preclinical data showed how translational PK-PD modeling might be a tool to help to inform the choice of the doses in FIH studies.

Keyphrases

palliative care
high intensity
electronic health record
physical activity
stem cells
resistance training
mesenchymal stem cells
data analysis